BioAge Labs announced Tuesday that its investigational cardiovascular drug BGE-102 achieved an 86% reduction in high-sensitivity C-reactive protein (hs-CRP) in a Phase 1 study of patients with obesity and elevated inflammation. The 60-milligram dose produced similar results to a 120-milligram dose after three weeks, with 87% of patients reaching hs-CRP levels below 2 mg/liter, a threshold associated with lower cardiovascular risk. The results position BGE-102 as a potential pill-based therapy for cardiovascular risk prevention. The announcement reflects a broader pharmaceutical industry trend of targeting inflammation to treat chronic conditions.
BGE-102 Phase 1 Study Results and Inflammation Reduction
- ▪Patients taking a 60-milligram dose of BGE-102 experienced an 86% reduction in high-sensitivity C-reactive protein (hs-CRP) after three weeks
- ▪87% of patients taking the 60-milligram dose of BGE-102 achieved hs-CRP levels of less than 2 mg/liter
- ▪hs-CRP levels of less than 2 mg/liter are thought to be associated with a lower risk of cardiovascular complications
- ▪BioAge Labs announced the BGE-102 Phase 1 study results on Tuesday, April 21, 2026
- ▪BioAge Labs conducted a Phase 1 study of BGE-102 in people with obesity and elevated inflammation levels
- ▪The 60-milligram dose of BGE-102 produced a similar level of hs-CRP reduction as a higher 120-milligram dose in the Phase 1 study
Targeting Inflammation for Cardiovascular Risk Prevention
- ▪BGE-102 is an investigational pill for cardiovascular risk prevention
- ▪More drug companies are targeting inflammation as a way to treat a range of chronic conditions
- ▪BGE-102 significantly reduced inflammation in an early study
Perspective of BioAge Labs
- ▪BioAge Labs characterizes BGE-102 as significantly reducing inflammation markers in the early-stage clinical study
- ▪BioAge Labs views the 86% reduction in hs-CRP achieved by BGE-102 as representing potential progress in heart disease prevention
Perspective of Pharmaceutical industry observers
- ▪The pharmaceutical industry is increasingly targeting inflammation as a therapeutic approach for treating a range of chronic conditions
Story comments
Loading comments…